rosiglitazone has been researched along with Diabetes Mellitus in 163 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (3.07) | 18.2507 |
| 2000's | 101 (61.96) | 29.6817 |
| 2010's | 52 (31.90) | 24.3611 |
| 2020's | 5 (3.07) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Fujita, T; Fujiwara, T; Honma, H; Horikoshi, H; Kaneko, T; Oguchi, M; Ohsumi, J; Sakakibara, S; Serizawa, N; Tanaka, A; Wada, K | 1 |
| Ardecky, R; Broderick, CL; Brooks, DA; Dominianni, SJ; Etgen, GJ; Faul, MM; Karanewsky, DS; Kauffman, RF; McCarthy, JR; Montrose-Rafizadeh, C; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, J; Warshawsky, AM; Winneroski, LL | 1 |
| Bajji, AC; Chakrabarti, R; Juluri, S; Kalchar, S; Lohray, BB; Lohray, VB; Mamidi, NV; Misra, P; Padakanti, S; Poondra, RR; Rajagopalan, R; Vikramadithyan, RK | 1 |
| Acton, JJ; Berger, J; Black, RM; Colwell, L; Doebber, TW; Jones, AB; Macnaul, KL; Moller, DE; Wood, HB | 1 |
| Almaden, JV; Bailey, S; Barnum, SJ; Carlson, TJ; Christie, LC; Do, QQ; Fraser, JD; Hess, M; Humphries, PS; Kellum, J; Kim, YH; McClellan, GA; Ogilvie, KM; Simmons, BH; Skalitzky, D; Sun, S; Wilhite, D; Zehnder, LR | 1 |
| Almaden, JV; Barnum, SJ; Carlson, TJ; Do, QQ; Fraser, JD; Hess, M; Humphries, PS; Kim, YH; Ogilvie, KM; Sun, S | 1 |
| Giri, S; Goel, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Pingali, H; Shah, S; Zaware, P | 1 |
| Araki, K; Arita, T; Furukawa, A; Hayashi, S; Kuroha, M; Matsui, Y; Ohsumi, J; Satoh, S; Wakabayashi, K | 1 |
| Abad, MC; Askari, HB; De, D; Gaul, MD; Geisler, JG; Kasturi, J; Kemmerer, M; Kim, AJ; Lenhard, JM; Lin, L; Liu, J; O'Neill, JC; Patch, RJ; Player, MR; Rentzeperis, D; Searle, LL; Zhu, X | 1 |
| Fan, L; Jiang, L; Song, XL; Wang, H; Xu, J; Yan, JF; Yang, DC; Zhou, GM | 1 |
| Chang, FR; Chuang, DW; El-Shazly, M; Hsieh, CT; Hsieh, TJ; Tsai, YH; Wu, SF; Wu, YC; Yen, CT | 1 |
| Dowarah, J; Singh, VP | 1 |
| Chen, S; Guo, Q; Huang, Y; Ma, L; Wang, J; Yang, R; Zhang, C; Zhao, S; Zhao, X | 1 |
| Cucullo, L; Sivandzade, F | 1 |
| Jat, RK; Mohammed, T; Momina, SS; Paladugu, ND; Sanapalli, BKR | 1 |
| Christensen-Dalsgaard, M; Eid, J; Grønlund, RV; Hansen, HH; Jelsing, J; Madsen, MR; Madsen, MSA; Mikkelsen, M; Rigbolt, K; Sommer, M; Vrang, N | 1 |
| Bandhakavi, S; Chen, M; Dirven, H; Fitch, SE; Kincaid, B; Leenaars, CHC; Mehta, J; Pound, P; Ram, R; Tsaioun, K; Vist, GE; Wright, RA | 1 |
| Dinney, CP; Ferguson, JE; Kamat, AM; Li, R; McConkey, DJ; Metcalfe, MJ; Mokkapati, S; Navai, N; Nogueras González, GM; Sahai, SK | 1 |
| Rawson, NS; Terres, JA | 1 |
| Tucker, ME | 1 |
| Gaekens, M; Gallacher, DJ; Hemmeryckx, B; Lijnen, HR; Lu, HR | 1 |
| Chen, R; Jia, Z; Kakizoe, Y; Liu, G; Liu, M; Sun, Y; Yang, B; Yang, KT; Yang, T; Zhou, L; Zhou, S | 1 |
| Mishra, P; Rath, SK; Singh, SV; Srivastava, P; Sultana, S; Verma, AK | 1 |
| Mitka, M | 1 |
| Prasad, V | 1 |
| Abete, P; Bellia, A; Cacciatore, F; Capuani, B; Dave, KR; De Marchis, ML; Della-Morte, D; Donadel, G; Dong, C; Ferroni, P; Fogliame, G; Guadagni, F; Lauro, D; Pacifici, F; Palmirotta, R; Pastore, D; Pileggi, A; Rehni, AK; Ricordi, C; Roselli, M; Rundek, T; Sbraccia, P | 1 |
| Geng, B; He, J; Jiang, H; Kuang, J; Liu, Q; Mo, L; Xu, C; Xu, G | 1 |
| Doblhammer, G; Fink, A; Heneka, MT | 1 |
| Bai, Y; Fan, XM; Liang, QL; Luo, GA; Sun, H; Wang, YM | 1 |
| Cho, DH; Jo, I; Kim, SA; Park, JH; Park, JY; Seo, J; Song, KH | 1 |
| Ahuja, V; Birge, JR; Budiman-Mak, E; Cooper, JM; Emanuele, N; Huang, ES; Sohn, MW; Syverson, C | 1 |
| Cai, L; He, D; He, X; Li, L; Li, S; Su, X; Wang, K; Yang, X; Zou, Z | 1 |
| Fu, H; Gaydos, BL; Heine, RJ; Hoogwerf, BJ; Manner, DH; Moscarelli, E | 1 |
| Aiello, LP; Child, A; Folkman, J; Shen, LQ; Weber, GM | 1 |
| Banz, WJ; Bollaert, M; Chickris, N; Higginbotham, A; Iqbal, MJ; Rockway, S | 1 |
| Bachmann, M; Dissmann, JP; Frank, S; Geisslinger, G; Goren, I; Pfeilschifter, J; Sader, R; Schiefelbein, D; Schmidt, H; Seitz, O | 1 |
| Hoffstad, O; Margolis, DJ; Strom, BL | 1 |
| Levin, R; Setoguchi, S; Solomon, DH; Winkelmayer, WC | 1 |
| Arduç, A; Aydin, Y; Berker, D; Ergün, B; Guler, S; Ustün, I | 1 |
| Lazar, MA; Lefterova, MI; Schupp, M; Steger, DJ; Tomaru, T | 1 |
| Parashar, A | 1 |
| Gomes, T; Juurlink, DN; Lipscombe, LL; Mamdani, MM | 1 |
| Braga, MF; Leiter, LA | 1 |
| Cho, JH; Kim, JW; Lee, SH; Park, HS; Sun, C; Yang, CW; Yang, JH; Yoon, KH | 1 |
| Dzanković, F; Macić-Dzanković, A; Pojskić, B; Velija-Asimi, Z | 1 |
| Homem-de-Mello, P; Honório, KM; Maltarollo, VG | 1 |
| Chu, SH; Chun, SH; Li, AH | 1 |
| Detsky, AS; Tomlinson, G | 1 |
| Baker, PR; Batthyany, CI; Bonacci, G; Chen, CS; Chen, YE; Cole, MP; Freeman, BA; Garcia-Barrio, MT; Golin-Bisello, F; Groeger, AL; Hallis, TM; Khoo, NK; Li, Y; Motanya, UN; Rudolph, TK; Rudolph, V; Schopfer, FJ; Woodcock, SR; Xu, HE; Zhang, J | 1 |
| Bassaganya-Riera, J; Guri, AJ; Hontecillas, R | 1 |
| McCoy, CP; Montori, VM; Murad, MH; Wang, AT | 1 |
| Asghari, S; Carpentier, AC; Courteau, J; Vanasse, A | 1 |
| Nissen, SE | 1 |
| Abassi, Z; Collins-Racie, L; Diblasio-Smith, L; Feuerstein, GZ; Goltsman, I; Lavallie, ER; Liu, X; Mounts, WM; Rutkowski, JL; Wang, X; Winaver, J; Xu, X; Zhan, Y | 1 |
| Kean, S | 1 |
| Nissen, SE; Wolski, K | 1 |
| Gori, T; Parker, JD; Perampaladas, K | 1 |
| Godlee, F | 1 |
| Dogra, V; El-Bejjani, D; Harrill, D; Hileman, C; McComsey, GA; O'Riordan, MA; Rizk, N; Ross, AC; Storer, N; Tungsiripat, M | 1 |
| Asensio-Sánchez, MJ; Asensio-Sánchez, VM; Gómez-Ramírez, V | 1 |
| Gale, EA | 1 |
| Avezum, A; Bergenstal, RM; Bosch, J; Chiasson, JL; Garrido, M; Gerstein, HC; Joldersma, L; Jung, H; MacKinnon, I; Mohan, V; Rao, PV; Yusuf, S; Zinman, B | 1 |
| Abadie, E; Blind, E; de Graeff, PA; Dunder, K | 1 |
| Lipska, KJ; Ross, JS | 1 |
| Komaroff, AL | 1 |
| Czernik, PJ; Huang, S; Krings, A; Lecka-Czernik, B; Lu, Y; Rahman, S | 1 |
| Bruedigam, C; Chiba, H; Eijken, M; Koedam, M; van Leeuwen, JP | 1 |
| Li, YC; Lu, YC | 1 |
| Chen, YC; Chen, YJ; Hsiao, FC; Kao, YH; Lee, TI; Lin, YK | 1 |
| Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP | 1 |
| Chao, TH; Chen, IC; Chen, JY; Lee, WH; Li, YH; Pan, HA; Tsai, WC; Tseng, SY | 1 |
| Cockerill, GW; Pirianov, G; Torsney, E | 1 |
| Kuehn, BM | 1 |
| Chen, X; Yang, L; Zhai, SD | 1 |
| D'hooge, J; Gallacher, DJ; Hemmeryckx, B; Himmelreich, U; Hoylaerts, MF; Lijnen, HR; Rong Lu, H; Swinnen, M | 1 |
| Aleksunes, LM; Reagan, LA; Vergara, CM; Wang, F | 1 |
| Belz, U; Herling, AW; Juretschke, HP; Kalisch, J; Kleinschmidt, E; Kramer, W; Kuhlmann, J; Neumann-Haefelin, C; Stein, M | 1 |
| Ida, M; Kurosaki, E; Nakano, R; Shibasaki, M; Shikama, H; Shimaya, A; Suzuki, T; Yoshida, S | 1 |
| Viberti, GC | 1 |
| Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF | 1 |
| Allcock, NM; Manley, HJ | 1 |
| Cheng, J; Dey, D; Gowri, M; Gross, C; Medicherla, S; Nag, B; Neogi, P; Reaven, GM; Sharma, SD | 1 |
| Kim, HS; Kim, MS; Koh, EH; Lee, KU; Park, HS; Park, JY; Youn, JH; Youn, JY | 1 |
| Chilton, RJ; Stolar, MW | 1 |
| Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Poulsen, MK | 1 |
| Cowan, D; Kaski, JC; Sidhu, JS | 1 |
| Singh, N | 1 |
| Al-Haddad, W; Aljada, A; Dandona, P; Dhindsa, S; Ghanim, H; Hofmeyer, D; Mohanty, P; Syed, T; Tripathy, D | 1 |
| Bosch, J; Gerstein, HC; Holman, R; Pogue, J; Yusuf, S | 1 |
| Bondy, G; Elliott, T; Frohlich, J; Harris, M; Montaner, J; Normén, L | 1 |
| Bai, XY; Goltzman, D; Karaplis, AC; Miao, D; Sorocéanu, MA; Su, H | 1 |
| Ferrannini, E | 1 |
| Banz, WJ; Davis, J; Iqbal, MJ; Peterson, R | 1 |
| Herget-Rosenthal, S; Janssen, O; Kribben, A; Mann, K; Patschan, D; Philipp, T; Pietruck, F; Van, TN; Witzke, O | 1 |
| Ergün, I; Keven, K | 1 |
| Wellington, K | 1 |
| Hunt, MJ; Morton, AJ | 1 |
| Baumelou, A; Buhaescu, I; Deray, G; Heurtier, A; Izzedine, H; Launay-Vacher, V | 1 |
| Lai, MY; Su, DH; Wu, HP | 1 |
| Bach, H; Bachem, M; Gizard, F; Haug, C; Hombach, V; Huber, R; Kapfer, X; Koenig, W; Marx, N; März, W; Meisner, F; Noak, A; Staels, B; Stojakovic, T; Sunder-Plassmann, L; Walcher, D | 1 |
| Averbukh, Z; Berman, S; Efrati, S; Feldman, L; Rapoport, M; Weissgarten, J | 1 |
| Dolff, S; Heemann, U; Janssen, OE; Kribben, A; Mann, K; Philipp, T; Pietruck, F; Türk, T; Witzke, O | 1 |
| Fan, SC; He, CT; Hsieh, CH; Hsing Lee, C; Hung, YJ; Kuo, SW; Lin, SH; Pei, D; Sheu, WH | 1 |
| Esposito, K; Giugliano, D | 1 |
| Aiello, LP; Clermont, A; Della Vecchia, K; King, GL; Kondo, T; Mastumoto, M; Rask-Madsen, C; Sotiropoulos, KB; Takahashi, J; Yasuda, Y | 1 |
| Albert, AJ; Cong, Z; Gabbay, RA; Gilliland, KL; Liu, W; Mauger, DT; Nelson, AM; Rosamilia, LL; Sivarajah, S; Thiboutot, DM; Trivedi, NR | 1 |
| Allen, T; Bell, A; Clemens, LE; Gregoire, F; Gustafson, TA; Moodie, SA; Muscat, GE; Smith, A; Zhang, F | 1 |
| Campbell, IW; Mariz, S | 1 |
| Phatak, HM; Yin, DD | 1 |
| Chiang, CK; Ho, TI; Hsu, SP; Hung, KY; Pai, MF; Peng, YS; Wu, KD; Yang, SY | 1 |
| Scheen, AJ | 1 |
| Mohan, V | 1 |
| Ruiz, J | 1 |
| Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S | 1 |
| Asano, S; Hansen, MK; Higashiyama, H; Kinoshita, M; McVey, MJ; Okamoto, Y; Rong, JX | 1 |
| Hitch, WJ; Jackson, VL; Scott, MA | 1 |
| Ledford, H | 1 |
| Wadman, M | 2 |
| Couzin, J | 1 |
| Goldberg, RB | 1 |
| Psaty, B | 1 |
| Fishman, I; Guttmann, H; Keidar, S; Shapira, C; Stam, T | 1 |
| Akin, F; Bastemir, M; Yaylali, GF | 1 |
| Banz, WJ; Bollaert, M; Chickris, N; Higginbotham, DA; Iqbal, MJ; James, B; Murphy, L; Peterson, R | 1 |
| D'Arrigo, T | 1 |
| Bloomgarden, ZT | 1 |
| Filson, S | 1 |
| Colca, JR | 1 |
| Comarow, A | 1 |
| Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM | 1 |
| Burton, B | 1 |
| Alter, DA; Gomes, T; Hux, JE; Juurlink, DN; Lévesque, LE; Lipscombe, LL | 1 |
| Mikhail, N | 2 |
| Best, JD; Fairley, KF; Farish, S; Kincaid-Smith, P; Proietto, J | 1 |
| Vastag, B | 1 |
| Goldfine, AB | 1 |
| Altmaier, E; Graber, A; Mewes, HW; Ramsay, SL; Suhre, K; Weinberger, KM | 1 |
| Ceska, R; Stulc, T | 1 |
| Achtari Jeanneret, L; Barras-Moret, AC; Carron, P; Deriaz-Chessex, S; Donzé, J; Fournier, Y; Gachoud, D; Moix, PA; Monti, M; Rossier, A; Wilson, P | 1 |
| Ailhaud, G; Amri, EZ; Cawthorne, MA; Gaillard, D; Grimaldi, PA; Ibrahimi, A; Teboul, L; Young, P | 1 |
| Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
| Burris, TP; Cryan, E; Demarest, KT; Osborne, MC; Pelton, PD; Zhou, L | 1 |
| Kadowaki, T | 1 |
| Arch, JR; Buckingham, RE; Cai, XJ; Lister, CA; Pickavance, L; Wilding, J; Williams, G; Wilson, S | 1 |
| Reddy, SS | 1 |
| Chapman, H; Gould, GW; Lister, CA; Maier, VH; Melvin, DR; Murphy, GJ | 1 |
| Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM | 1 |
| Boehm, M; Crombie, DL; Davies, PJ; Depre, C; Heyman, RA; Leibowitz, MD; Liu, S; Nagy, L; Singh Ahuja, H; Tontonoz, P | 1 |
| Buckingham, RE; Finegood, DT; Kojwang, D; Leonard, T; McArthur, MD; Thomas, MJ; Topp, BG | 1 |
| Atzpodien, E; Bedoucha, M; Boelsterli, UA | 1 |
| Oka, Y; Yonezawa, N | 1 |
| Pospísilová, Y | 1 |
| Lund, S; Pedersen, O; Vestergaard, H | 1 |
| Anderson, JW; Frederich, RC; Konz, EC; Reynolds, LR | 1 |
28 review(s) available for rosiglitazone and Diabetes Mellitus
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
Anti-diabetic drugs recent approaches and advancements.
Topics: Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Molecular Structure; Structure-Activity Relationship | 2020 |
Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Liver; Rosiglitazone; Troglitazone | 2021 |
Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus; Humans; Pharmacogenetics; Pioglitazone; Precision Medicine; Risk Factors; Rosiglitazone; Thiazolidinediones; Troglitazone | 2014 |
Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Drug Discovery; Drug Evaluation, Preclinical; Drug Industry; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2016 |
Role of renin-angiotensin system blockade in patients with diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Progression; Endothelium, Vascular; Humans; Ramipril; Renin-Angiotensin System; Rosiglitazone; Tetrazoles; Thiazolidinediones; Valine; Valsartan; Vasodilation; Ventricular Function | 2009 |
Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.
Topics: Conflict of Interest; Cross-Sectional Studies; Diabetes Mellitus; Disclosure; Drug Industry; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
Topics: Biomarkers; Cardiovascular Diseases; Confidence Intervals; Diabetes Mellitus; Europe; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
The impact of rosiglitazone on nitric oxide bioavailability and endothelial function.
Topics: Diabetes Mellitus; Endothelium, Vascular; Humans; Nitric Oxide; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2010 |
Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection?
Topics: Animals; Aortic Aneurysm, Abdominal; Diabetes Mellitus; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Molecular Targeted Therapy; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2013 |
Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2012 |
Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Topics: Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diuresis; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Metformin; Middle Aged; Obesity; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hemodynamics; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2003 |
Rosiglitazone/Metformin.
Topics: Animals; Diabetes Mellitus; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Therapeutic Equivalency; Thiazolidinediones | 2005 |
PPAR-gamma-agonists' renal effects.
Topics: Animals; Chromans; Diabetes Mellitus; Hemodynamics; Humans; Hypoglycemic Agents; Kidney; PPAR gamma; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Beta-cell preservation with thiazolidinediones.
Topics: Chromans; Diabetes Mellitus; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials.
Topics: Diabetes Mellitus; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Time Factors | 2006 |
Pharmacokinetic interactions with thiazolidinediones.
Topics: Diabetes Mellitus; Drug Interactions; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies; Humans; Premedication; Ramipril; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?
Topics: Adult; Aged; Carotid Arteries; Clinical Trials as Topic; Diabetes Mellitus; Disease Progression; Female; Humans; Hyperglycemia; Insulin; Male; Middle Aged; Ramipril; Rosiglitazone; Thiazolidinediones | 2007 |
The rough road for rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Heart Failure; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
Why should we avoid the use of rosiglitazone?
Topics: Diabetes Mellitus; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Rosiglitazone; Thiazolidinediones | 2008 |
Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; PPAR gamma; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
[Insulin-sensitizing agents].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
[Rosiglitazone(BRL-49653)].
Topics: Animals; Controlled Clinical Trials as Topic; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Lipid Metabolism; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[News in oral antidiabetic therapy].
Topics: Administration, Oral; Carbamates; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
18 trial(s) available for rosiglitazone and Diabetes Mellitus
| Article | Year |
|---|---|
Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome.
Topics: Biomarkers; C-Reactive Protein; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metabolic Syndrome; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Uric Acid | 2009 |
Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo.
Topics: Adult; Anti-Retroviral Agents; Biomarkers; Cardiovascular Diseases; Carotid Artery, Common; Cholesterol; Cytokines; Diabetes Mellitus; Endothelium, Vascular; Extremities; Female; HIV Infections; Humans; Inflammation; Lipodystrophy; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Tunica Intima | 2011 |
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.
Topics: Aged; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Ramipril; Rosiglitazone; Thiazolidinediones | 2011 |
Effects of rosiglitazone on the cardiovascular profile in postmenopausal women without diabetes mellitus: interplay of thiazolidinediones and hormone therapy.
Topics: Aged; Body Size; Cardiovascular System; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Female; Hormone Replacement Therapy; Humans; Hypoglycemic Agents; Leukocyte Count; Matrix Metalloproteinase 9; Middle Aged; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Postmenopause; Prospective Studies; Risk Factors; Rosiglitazone; Serine Proteinase Inhibitors; Thiazolidinediones | 2012 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glycated Hemoglobin; Glycolysis; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2003 |
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus; Endothelium, Vascular; Female; Fibrinogen; Humans; Insulin Resistance; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Vasodilator Agents | 2003 |
Evidence for a potent antiinflammatory effect of rosiglitazone.
Topics: Adult; Aged; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; I-kappa B Proteins; Insulin; Insulin Resistance; Intercellular Adhesion Molecule-1; Leukocytes, Mononuclear; Male; Middle Aged; NF-kappa B; Obesity; Rosiglitazone; Solubility; Thiazolidinediones; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2004 |
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
Topics: Adult; Aged; Antihypertensive Agents; Body Mass Index; Body Size; Diabetes Mellitus; Diabetes, Gestational; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Life Style; Male; Middle Aged; Patient Selection; Pregnancy; Ramipril; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation.
Topics: Diabetes Mellitus; Edema; Female; Humans; Hypoglycemic Agents; Kidney Transplantation; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2005 |
Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
Topics: Aged; Blood Glucose; Body Mass Index; C-Reactive Protein; Carotid Stenosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Collagen; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Middle Aged; Rosiglitazone; Serum Amyloid A Protein; Thiazolidinediones | 2006 |
Repaglinide in the management of new-onset diabetes mellitus after renal transplantation.
Topics: Carbamates; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Kidney Transplantation; Male; Middle Aged; Piperidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Topics: Adiponectin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus; Disease Progression; Female; Glucose Intolerance; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Peroxisome proliferator-activated receptors increase human sebum production.
Topics: Adult; Cell Line, Transformed; Diabetes Mellitus; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isotretinoin; Ligands; Lipogenesis; Male; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Rosiglitazone; Sebaceous Glands; Sebum; Thiazolidinediones | 2006 |
Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects.
Topics: C-Reactive Protein; Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver Function Tests; Male; Middle Aged; Prospective Studies; Renal Dialysis; Rosiglitazone; Safety; Thiazolidinediones; Virus Diseases | 2007 |
The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Diabetes Mellitus; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Male; Middle Aged; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Failure | 2007 |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Elasticity; Endothelium, Vascular; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Male; Metformin; Middle Aged; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilation | 2007 |
Reduction of proteinuria by rosiglitazone in non-diabetic renal disease.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; PPAR gamma; Proteinuria; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.
Topics: Biomarkers; Blood Pressure; Body Constitution; Body Mass Index; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Obesity; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Weight Loss | 2002 |
117 other study(ies) available for rosiglitazone and Diabetes Mellitus
| Article | Year |
|---|---|
Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones.
Topics: 3T3 Cells; Adipocytes; Animals; Biological Availability; Cell Differentiation; Diabetes Mellitus; Drug Design; Drug Evaluation, Preclinical; Heart; Hypoglycemic Agents; Imidazoles; Male; Mice; Organ Size; Rats; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 2000 |
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Propionates; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides | 2001 |
(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
Topics: Animals; Biological Availability; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Mice; Oxazines; Phenylpropionates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors; Triglycerides | 2001 |
Benzoyl 2-methyl indoles as selective PPARgamma modulators.
Topics: Animals; Benzoates; Diabetes Mellitus; Disease Models, Animal; Humans; Indoles; Inflammation Mediators; Ligands; Molecular Structure; PPAR gamma | 2005 |
Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
Topics: Animals; Blood Glucose; Body Weight; Cell Line, Tumor; Diabetes Mellitus; Ether; Humans; Hypoglycemic Agents; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Structure-Activity Relationship; Thiazolidinediones | 2006 |
Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
Topics: Animals; Blood Glucose; Body Weight; Cell Line, Tumor; Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Structure-Activity Relationship | 2006 |
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
Topics: Animals; Carboxylic Acids; Diabetes Mellitus; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred NOD; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Structure-Activity Relationship | 2008 |
Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.
Topics: Animals; Benzofurans; Crystallography, X-Ray; Diabetes Mellitus; Glucose; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Mice; Models, Molecular; PPAR gamma | 2010 |
Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.
Topics: Administration, Oral; Animals; Binding, Competitive; Biological Availability; Crystallography, X-Ray; Diabetes Mellitus; Dogs; ERRalpha Estrogen-Related Receptor; Ethers; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Macaca fascicularis; Male; Mice; Mice, Knockout; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Structure-Activity Relationship; Thiazolidinediones; Triglycerides | 2011 |
Synthesis and antidiabetic performance of β-amino ketone containing nabumetone moiety.
Topics: alpha-Glucosidases; Amines; Butanones; Diabetes Mellitus; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Ketones; Magnetic Resonance Spectroscopy; Models, Molecular; Nabumetone; Peroxisome Proliferator-Activated Receptors; Structure-Activity Relationship; Sulfanilamide; Sulfanilamides | 2012 |
Synthesis of chalcone derivatives as potential anti-diabetic agents.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Biological Transport, Active; Chalcones; Diabetes Mellitus; Glucose; Humans; Hypoglycemic Agents; Mice; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones | 2012 |
Effect of PPARγ on oxidative stress in diabetes-related dry eye.
Topics: Animals; Antioxidants; Diabetes Mellitus; Dry Eye Syndromes; Mice; Oxidative Stress; PPAR gamma; RNA, Messenger; Rosiglitazone | 2023 |
Anti-Diabetic Countermeasures Against Tobacco Smoke-Dependent Cerebrovascular Toxicity: Use and Effect of Rosiglitazone.
Topics: Animals; Blood-Brain Barrier; Brain; Cerebrovascular Disorders; Cotinine; Diabetes Mellitus; Humans; Hypoglycemic Agents; Male; Mice, Inbred C57BL; NF-E2-Related Factor 2; Nicotine; PPAR gamma; Rosiglitazone; Signal Transduction; Tobacco Smoking | 2019 |
Hypothesis validation of rosiglitazone a potential inhibitor against glycogen synthase kinase-3β, for the management of multifaceted pathophysiology of the diabetic wound: An insilico study.
Topics: Cell Proliferation; Diabetes Mellitus; Glycogen Synthase Kinase 3 beta; Humans; Molecular Docking Simulation; Rosiglitazone | 2020 |
Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice.
Topics: Animals; Bacteria; Diabetes Mellitus; Disease Models, Animal; Gastrointestinal Microbiome; Gene Expression Regulation; Host-Pathogen Interactions; Hypoglycemic Agents; Intestines; Male; Mice; PPAR gamma; Rosiglitazone; Signal Transduction; Transcriptome | 2021 |
Effects of thiazolidinedione in patients with active bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cystectomy; Diabetes Mellitus; Disease-Free Survival; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Neoplasm Staging; Pioglitazone; Retrospective Studies; Rosiglitazone; Survival Rate; Thiazolidinediones; Urinary Bladder Neoplasms | 2018 |
Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010.
Topics: Adverse Drug Reaction Reporting Systems; Canada; Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2013 |
FDA panel advises easing restrictions on rosiglitazone.
Topics: Diabetes Mellitus; Drug and Narcotic Control; Humans; Hypoglycemic Agents; Myocardial Infarction; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Effect of rosiglitazone on liver structure and function in genetically diabetic Akita mice.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Cholesterol, Dietary; Diabetes Mellitus; Diet, High-Fat; Fatty Liver; Gene Expression; Genotype; Liver; Male; Mice; Mice, Inbred C57BL; Organ Size; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides; Tyrosine | 2013 |
Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.
Topics: Animals; Aquaporin 2; Aquaporin 3; Biological Transport; Blood Glucose; Body Water; Diabetes Mellitus; Disease Models, Animal; Diuresis; Humans; Hypoglycemic Agents; Kidney; Male; Mice; Natriuresis; Osmolar Concentration; Plasma Volume; PPAR gamma; Rosiglitazone; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers; Solute Carrier Family 12, Member 1; Thiazolidinediones; Triglycerides; Water-Electrolyte Balance; Water-Electrolyte Imbalance; Weight Gain | 2013 |
Rosiglitazone induces cardiotoxicity by accelerated apoptosis.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cell Differentiation; Cell Line; Cell Survival; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Heart Diseases; Heme Oxygenase (Decyclizing); Hypoglycemic Agents; Male; Mice; Myocytes, Cardiac; NADPH Oxidases; NF-E2-Related Factor 2; Nitric Oxide Synthase; Oxidative Phosphorylation; Oxidative Stress; Protein Kinase C-delta; Rats; Rosiglitazone; Signal Transduction; Superoxides; Thiazolidinediones; Time Factors | 2014 |
FDA eases restrictions on the glucose-lowering drug rosiglitazone.
Topics: Death, Sudden, Cardiac; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Practice Patterns, Physicians'; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
Rosiglitazone, medical reversal, and back to basics for diabetes.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2014 |
Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Chromans; Cyclic AMP; Dexamethasone; Diabetes Mellitus; Fatty Acids, Nonesterified; Glucocorticoids; Hydrolysis; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Phosphorylation; Pioglitazone; Proto-Oncogene Proteins c-akt; Rats; Rosiglitazone; Signal Transduction; Thiazolidinediones; Triglycerides; Troglitazone | 2015 |
Effect of pioglitazone medication on the incidence of dementia.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Dementia; Diabetes Mellitus; Female; Germany; Humans; Hypoglycemic Agents; Incidence; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Proportional Hazards Models; Prospective Studies; Protective Factors; Rosiglitazone; Thiazolidinediones | 2015 |
[The mechanism of rosiglitazone compound based on network pharmacology].
Topics: Calcium Signaling; Cognitive Dysfunction; Computational Biology; Diabetes Mellitus; Humans; Pharmacology; Rosiglitazone; Thiazolidinediones | 2015 |
Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβ expression.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Cattle; Cell Adhesion; Diabetes Mellitus; Endothelial Cells; Humans; Hyperglycemia; I-kappa B Kinase; Inflammation; Monocytes; PPAR gamma; Rosiglitazone; Telmisartan; Thiazolidinediones; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.
Topics: Aged; Biomarkers; Blood Glucose; Delivery of Health Care, Integrated; Diabetes Mellitus; Drug Labeling; Drug Utilization Review; Female; Healthcare Disparities; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Practice Patterns, Physicians'; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; United States Food and Drug Administration | 2015 |
Alizarin Complexone Functionalized Mesoporous Silica Nanoparticles: A Smart System Integrating Glucose-Responsive Double-Drugs Release and Real-Time Monitoring Capabilities.
Topics: Anthraquinones; Diabetes Mellitus; Drug Delivery Systems; Fluorescence; Glucose; HeLa Cells; Humans; Insulin; Nanoparticles; Rosiglitazone; Silicon Dioxide; Thiazolidinediones | 2016 |
Rosiglitazone and delayed onset of proliferative diabetic retinopathy.
Topics: Aged; Angiogenesis Inhibitors; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Female; Humans; Hypoglycemic Agents; Longitudinal Studies; Macular Edema; Male; Medical Records; Middle Aged; PPAR gamma; Retrospective Studies; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Visual Acuity | 2008 |
A combination of CLA-DAG oil modifies the diabetic phenotype in male Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diglycerides; DNA, Complementary; Eating; Gene Expression; Hypoglycemic Agents; Insulin; Insulin Resistance; Kidney; Linoleic Acid; Liver; Muscle, Skeletal; Myocardium; Phenotype; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Triglycerides | 2008 |
Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated prote
Topics: Animals; Cell Survival; Cells, Cultured; Chromans; Diabetes Mellitus; Dose-Response Relationship, Drug; Enzyme Activation; Female; Immunohistochemistry; Keratinocytes; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; p38 Mitogen-Activated Protein Kinases; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone; Vascular Endothelial Growth Factor A; Wound Healing | 2008 |
Association between serious ischemic cardiac outcomes and medications used to treat diabetes.
Topics: Adult; Aged; Biguanides; Cohort Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Myocardial Ischemia; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2008 |
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2008 |
Severe hyponatremia due to rosiglitazone use in an elderly woman with diabetes mellitus: a rare cause of syndrome of inappropriate antidiuretic hormone secretion.
Topics: Aged, 80 and over; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Hyponatremia; Inappropriate ADH Syndrome; Rosiglitazone; Thiazolidinediones | 2008 |
Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins.
Topics: 3T3-L1 Cells; Adipocytes; Animals; CCAAT-Enhancer-Binding Protein-beta; CCAAT-Enhancer-Binding Proteins; Diabetes Mellitus; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin; Macrophages; Mice; PPAR gamma; Resistin; Response Elements; Retinoid X Receptor alpha; Rosiglitazone; Species Specificity; Thiazolidinediones | 2009 |
N-3 polyunsaturated fatty acids and statins in heart failure.
Topics: Diabetes Complications; Diabetes Mellitus; Fatty Acids, Unsaturated; Heart Failure; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2009 |
Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Consumer Product Safety; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Ontario; Pioglitazone; Registries; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone protects the pancreatic beta-cell death induced by cyclosporine A.
Topics: Animals; Cyclosporine; Cytoprotection; Diabetes Mellitus; Glucose Tolerance Test; Hypoglycemic Agents; Immunosuppressive Agents; Insulin; Insulin-Secreting Cells; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Transplantation | 2009 |
Theoretical study on the molecular and electronic properties of some substances used for diabetes mellitus treatment.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Models, Molecular; Pioglitazone; Quantitative Structure-Activity Relationship; Rosiglitazone; Thiazolidinediones | 2010 |
Association of proliferative diabetic retinopathy with insulin use and microalbuminuria.
Topics: Albuminuria; Angiogenesis Inhibitors; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Macular Edema; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Composite end points in randomized trials: there is no free lunch.
Topics: Decision Making; Diabetes Mellitus; Endpoint Determination; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Topics: 3T3-L1 Cells; Amino Acid Sequence; Amino Acid Substitution; Animals; Base Sequence; Blood Glucose; Cell Line; Diabetes Mellitus; DNA Primers; Fatty Acids, Unsaturated; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Ligands; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Molecular Sequence Data; Mutagenesis, Site-Directed; Nitro Compounds; Oleic Acid; PPAR gamma; Protein Binding; Protein Processing, Post-Translational; Protein Structure, Tertiary; Recombinant Proteins; Rosiglitazone; Signal Transduction; Tandem Mass Spectrometry; Thiazolidinediones | 2010 |
Abscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue: possible action of the cAMP/PKA/PPAR γ axis.
Topics: Abscisic Acid; Adipose Tissue; Animals; Blood Glucose; Cyclic AMP-Dependent Protein Kinases; Data Collection; Diabetes Mellitus; Glucose Intolerance; Inflammation; Insulin; Macrophages; Mice; Mice, Obese; Obesity; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone (Avandia) revisited.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2010 |
Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients.
Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Drug Prescriptions; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Logistic Models; Myocardial Infarction; Odds Ratio; Quebec; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2009 |
The painful truth.
Topics: Access to Information; Cholesterol, LDL; Diabetes Mellitus; Drug Industry; Heart Failure; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Ischemia; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-gamma activator rosiglitazone in rodents: a translational medicine investigation.
Topics: Animals; Biomarkers; Body Weight; Diabetes Mellitus; Echocardiography; Fibrosis; Gene Expression Regulation; Heart Failure; Hemodynamics; Hypoglycemic Agents; Immunohistochemistry; Myocarditis; Myocardium; Organ Size; PPAR gamma; Rats; Rats, Inbred Lew; Rats, Zucker; RNA; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical | 2010 |
Drug safety. Planned study of Avandia in doubt after FDA review.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Informed Consent; Patient Selection; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2010 |
Effective approach.
Topics: Diabetes Mellitus; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Health Care Rationing; Humans; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2010 |
Cardiovascular risk from drugs. Editor's reply.
Topics: Diabetes Mellitus; Harm Reduction; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2010 |
[Macular oedema due to rosiglitazone treatment in diabetes mellitus].
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Macular Edema; Middle Aged; Rosiglitazone; Thiazolidinediones | 2010 |
Therapy: The second time as farce: rosiglitazone and the regulators.
Topics: Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Rosiglitazone: a European regulatory perspective.
Topics: Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2011 |
Switching from rosiglitazone: thinking outside the class.
Topics: Blood Glucose; Cardiovascular Diseases; Decision Making; Diabetes Mellitus; Drug Labeling; Evidence-Based Medicine; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones | 2011 |
Ask the doctor. Because of the recent news about Avandia, my physician has advised me to stop taking it. Is that wise?
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2011 |
Bone marrow fat has brown adipose tissue characteristics, which are attenuated with aging and diabetes.
Topics: Adipocytes; Adipose Tissue, Brown; Adiposity; Aging; Animals; Biomarkers; Bone and Bones; Bone Marrow; Cell Count; Diabetes Mellitus; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Organ Specificity; Phenotype; Rosiglitazone; Thiazolidinediones; Tibia | 2012 |
Opposing actions of rosiglitazone and resveratrol on mineralization in human vascular smooth muscle cells.
Topics: Apoptosis; Atherosclerosis; Caspases; Cell Differentiation; Cells, Cultured; Diabetes Mellitus; Humans; Hypoglycemic Agents; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Resveratrol; Rosiglitazone; Signal Transduction; Stilbenes; Thiazolidinediones; Up-Regulation | 2011 |
How doctors practice evidence-based medicine.
Topics: Adult; Age Factors; Diabetes Mellitus; Evidence-Based Medicine; Female; Health Knowledge, Attitudes, Practice; Humans; Hypoglycemic Agents; Male; Medicine; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Residence Characteristics; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2013 |
Rosiglitazone induces arrhythmogenesis in diabetic hypertensive rats with calcium handling alteration.
Topics: Animals; Arrhythmias, Cardiac; Calcium Signaling; Diabetes Mellitus; Hypertension; Male; Myocytes, Cardiac; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Thiazolidinediones | 2013 |
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome | 2011 |
IOM urges FDA to be more aggressive in monitoring safety of approved drugs.
Topics: Diabetes Mellitus; Drug Approval; Humans; Hypoglycemic Agents; National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; Patient Safety; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2012 |
Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?
Topics: Adiposity; Animals; Diabetes Mellitus; Genotype; Heart; Heterozygote; Hypertrophy; Male; Mice; Rosiglitazone; Thiazolidinediones | 2013 |
Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Lipid Metabolism; Liver; Longitudinal Studies; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Organ Size; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
Topics: 3T3 Cells; Adipose Tissue; Animals; Binding Sites; Biological Transport; Carrier Proteins; Diabetes Mellitus; Disease Models, Animal; Fatty Acid-Binding Proteins; Fish Proteins; Glucokinase; Humans; Hypoglycemic Agents; Ion Channels; Liver; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Oxadiazoles; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Trypsin; Tumor Cells, Cultured; Uncoupling Protein 1 | 2003 |
[When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis.
Topics: Aged; Aged, 80 and over; Blood Pressure; Comorbidity; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Outpatients; Pioglitazone; Renal Dialysis; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2003 |
A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus; Dose-Response Relationship, Drug; Glycogen; Humans; Hypoglycemic Agents; Insulin; Mice; Mice, Inbred C57BL; Mice, Obese; Radioligand Assay; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection | 2003 |
Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Topics: Adipose Tissue; Animals; Basal Metabolism; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids; Fenofibrate; Glycogen; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Islets of Langerhans; Male; Muscle, Skeletal; Obesity; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Viscera | 2003 |
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone and heart failure: long-term vigilance.
Topics: Aged; Diabetes Mellitus; Edema; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors | 2004 |
Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Female; Fenofibrate; HIV Seropositivity; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.
Topics: Animals; Apoptosis; Biomarkers; Blood Glucose; Bone and Bones; Bone Density; Calcium; Cells, Cultured; Diabetes Mellitus; Histocytochemistry; Hypoglycemic Agents; Image Processing, Computer-Assisted; Leptin; Male; Mice; Mice, Inbred C57BL; Osteoblasts; Osteocalcin; Osteocytes; Parathyroid Hormone; Rosiglitazone; Thiazolidinediones | 2004 |
Rosiglitazone and lipid metabolism.
Topics: Adipose Tissue; Diabetes Mellitus; Humans; Hypoglycemic Agents; Lipid Metabolism; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2005 |
Gene expression and adiposity are modified by soy protein in male Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Body Composition; Caseins; Diabetes Mellitus; Diet; Dietary Proteins; Gene Expression; Hypoglycemic Agents; Isoflavones; Lipids; Liver; Male; Obesity; Organ Size; Polymerase Chain Reaction; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2004 |
Short-term rosiglitazone treatment in renal transplant recipients.
Topics: Cyclosporine; Diabetes Mellitus; Drug Administration Schedule; Humans; Hypoglycemic Agents; Immunosuppressive Agents; Insulin Resistance; Kidney Transplantation; Rosiglitazone; Tacrolimus; Thiazolidinediones | 2005 |
Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.
Topics: Administration, Oral; Animals; Behavior, Animal; Diabetes Mellitus; Disease Models, Animal; Exocytosis; Glucose Intolerance; Glyburide; Glycosuria; Huntington Disease; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Neurologic Mutants; Mice, Transgenic; Rosiglitazone; Thiazolidinediones | 2005 |
Liver failure in a patient receiving rosiglitazone therapy.
Topics: Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Tests; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats.
Topics: Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Diabetes Mellitus; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Glomerular Mesangium; In Situ Nick-End Labeling; PPAR gamma; Pregnancy; Pregnancy, Animal; Probability; Rats; Rats, Sprague-Dawley; Reference Values; Risk Factors; Rosiglitazone; Sensitivity and Specificity; Statistics, Nonparametric; Streptozocin; Thiazolidinediones; Transforming Growth Factor beta | 2006 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones | 2006 |
Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.
Topics: Adipose Tissue; Animals; Capillary Permeability; Diabetes Mellitus; Edema; Enzyme Activation; Enzyme Inhibitors; Hypoglycemic Agents; Indoles; Male; Maleimides; Mice; Mice, Knockout; Obesity; PPAR gamma; Protein Kinase C; Protein Kinase C beta; Rats; Rats, Zucker; Receptor, Insulin; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A; Weight Gain | 2006 |
Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cell Line; Diabetes Mellitus; Gene Expression Regulation; Halofenate; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Mice; Mice, Obese; PPAR gamma; Protein Structure, Tertiary; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Two-Hybrid System Techniques | 2006 |
DREAM study and its impact on India.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Humans; Hypoglycemic Agents; India; Prediabetic State; Ramipril; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2006 |
[The DREAM of diabetes prevention].
Topics: Antihypertensive Agents; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones | 2007 |
Comparison of mitochondrial and macrophage content between subcutaneous and visceral fat in db/db mice.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Cell Count; Cell Shape; Cell Size; Chaperonin 60; Diabetes Mellitus; Disease Models, Animal; Intra-Abdominal Fat; Ion Channels; Macrophages; Male; Mice; Mitochondria; Mitochondrial Proteins; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones; Uncoupling Protein 1 | 2007 |
Hospital admission associated with Medicare Part D "doughnut hole".
Topics: Aged; Diabetes Mellitus; Drug Prescriptions; Female; Humans; Hypoglycemic Agents; Insurance, Pharmaceutical Services; Medicare; Metformin; Patient Readmission; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Weighing up the evidence.
Topics: Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus; Humans; Meta-Analysis as Topic; Myocardial Infarction; Patients; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2007 |
Man on a mission.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; History, 21st Century; Humans; Lactones; Quinolines; Rosiglitazone; Sulfones; Thiazolidinediones | 2007 |
Drug safety. Heart attack risk overshadows a popular diabetes therapy.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus; Drug Industry; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Myocardial Infarction; Risk; Risk Factors; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Heart-stopping news. The diabetes drug Avandia is under fire: what you should know. Interview by Avery Comarow.
Topics: Blood Glucose; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Product Surveillance, Postmarketing; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2007 |
High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Preventing diabetes, Part II: an action plan.
Topics: Diabetes Mellitus; Diet; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Obesity; Rosiglitazone; Smoking; Thiazolidinediones; Weight Loss | 2007 |
Ginseng modifies the diabetic phenotype and genes associated with diabetes in the male ZDF rat.
Topics: Administration, Oral; Animals; Blood Glucose; Cholesterol; Diabetes Mellitus; Diet; DNA Primers; Gene Expression Regulation; Hypoglycemic Agents; Male; Panax; Phytotherapy; Plant Extracts; Polymerase Chain Reaction; PPAR gamma; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones; Triglycerides | 2007 |
Avandia and your heart.
Topics: Diabetes Mellitus; Heart Arrest; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; United States | 2007 |
The Avandia debate.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones | 2007 |
American Diabetes Association - 67th scientific sessions.
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2007 |
67 th annual meeting of the American Diabetes Association.
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Rosiglitazone; Thiazolidinediones | 2007 |
Avandia in perspective.
Topics: Blood Glucose; Diabetes Mellitus; Exercise; Health Behavior; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Obesity; Risk-Taking; Rosiglitazone; Thiazolidinediones; United States | 2007 |
Health official speaks out about row over drug critic.
Topics: Diabetes Mellitus; Drug Industry; History, 20th Century; History, 21st Century; Humans; Meta-Analysis as Topic; Myocardial Infarction; Research Personnel; Rosiglitazone; Thiazolidinediones | 2007 |
Diabetes expert accuses drug company of "intimidation".
Topics: Diabetes Mellitus; Drug Industry; Humans; Hypoglycemic Agents; Interprofessional Relations; Organizational Policy; Rosiglitazone; Thiazolidinediones | 2007 |
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
Topics: Aged; Aged, 80 and over; Cause of Death; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Thiazolidinediones | 2007 |
Cardiovascular safety of low-dose rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Reviewer leaked Avandia study to drug firm.
Topics: Diabetes Mellitus; Drug Industry; Ethics, Professional; Humans; Meta-Analysis as Topic; Myocardial Infarction; Peer Review, Research; Rosiglitazone; Thiazolidinediones; Truth Disclosure | 2008 |
Bioinformatics analysis of targeted metabolomics--uncovering old and new tales of diabetic mice under medication.
Topics: Amino Acids; Animals; Carnitine; Computational Biology; Diabetes Mellitus; Gluconeogenesis; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Models, Biological; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thiazolidinediones | 2008 |
[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents].
Topics: Accidental Falls; Aged; Albuterol; Anemia; Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Atrial Fibrillation; Attitude of Health Personnel; Benzazepines; Bronchitis, Chronic; Bronchodilator Agents; Cardiac Pacing, Artificial; Diabetes Mellitus; Endocarditis, Bacterial; Erythropoietin; Heart Failure; Heparin; Humans; Internal Medicine; Interprofessional Relations; Medical Staff, Hospital; Myocardial Infarction; Recombinant Proteins; Risk Management; Rosiglitazone; Salmeterol Xinafoate; Thiazolidinediones; Thromboembolism; Tolvaptan; Vasodilator Agents; Ventricular Dysfunction, Left; Workload | 2008 |
Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells.
Topics: 3T3 Cells; Adipose Tissue; Animals; Carrier Proteins; Cells, Cultured; Diabetes Mellitus; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression Regulation; Hypoglycemic Agents; Kinetics; Mice; Neoplasm Proteins; Nerve Tissue Proteins; Palmitates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 1994 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Topics: Adipocytes; Animals; Base Sequence; Carrier Proteins; Cells, Cultured; Chromans; Diabetes Mellitus; DNA Probes; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Female; Gene Expression Regulation; Genetic Techniques; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Molecular Sequence Data; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tretinoin; Troglitazone; Tumor Suppressor Proteins | 1999 |
Rosiglitazone maleate. Ketotifen fumarate.
Topics: Conjunctivitis, Allergic; Diabetes Mellitus; Drug Administration Schedule; Histamine H1 Antagonists; Humans; Hypoglycemic Agents; Ketotifen; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Hypothalamus; Insulin; Intracellular Signaling Peptides and Proteins; Leptin; Neuropeptides; Obesity; Orexins; Protein Precursors; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Transcription, Genetic | 2000 |
How should patients taking the discontinued diabetes drug troglitazone be managed?
Topics: Alanine Transaminase; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fat
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose Transporter Type 4; Hypoglycemic Agents; Immunoblotting; Insulin Resistance; Male; Membrane Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Qa-SNARE Proteins; R-SNARE Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vesicle-Associated Membrane Protein 3 | 2000 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; DNA; Female; Gene Expression Regulation; Glucose Intolerance; Hormones; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Antagonists; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nerve Growth Factor; Neutralization Tests; Obesity; Proteins; Resistin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2001 |
Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Liver; Male; Muscle, Skeletal; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Topics: Aging; Animals; Blood Glucose; Body Weight; Cell Death; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Organ Size; Pancreas; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus; Fatty Liver; Gene Expression; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Obesity; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Up-Regulation | 2001 |
Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism.
Topics: Adolescent; Adult; Apolipoproteins B; Body Mass Index; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mutation; Plasminogen Activator Inhibitor 1; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |